.After antibody-drug conjugate (ADC) specialist Seagen was sold to Pfizer in 2014 for a monstrous $4...
.On the heels of a phase 3 succeed that failed to thrill financiers, Ironwood Pharmaceuticals is act...
.Don't stop Monte Rosa Therapeutics currently. The Boston-based biotech is actually having a ball af...
.Welcome to recently's Chutes & Ladders, our summary of substantial leadership hirings, firings a...
.Commemorating his business's upsized going public (IPO), Septerna chief executive officer Jeffrey F...
.AbbVie has actually come back to the source of its own antipsychotic goliath Vraylar trying to find...
.GenSight Biologics is actually full weeks out of losing cash. Again. The biotech only has adequate ...
.Monopar Rehabs is actually recouping a medication from the scrap heap of AstraZeneca's uncommon ill...
.With brand-new data out on Arcus Biosciences' speculative HIF-2a inhibitor, one group of analysts e...
.After developing a genetics treatment relationship along with Dyno Therapies in 2020, Roche is back...
.Lundbeck is slashing guide worth of its own $250 thousand Abide Rehabs buyout in response to period...
.The assimilation of real-world information (RWD) right into protocol expediency and website assortm...
.At this year's Tough Biotech Summit in Boston ma, our experts caught up with leaders in the biotech...
.Merck & Co. is actually setting down $30 million ahead of time to acquire Yale spinout Modifi Bi...
.Alpha-9 Oncology has raised a $175 thousand collection C round to money its clinical-stage radiopha...
.Eye medication manufacturer Ocuphire Pharma is actually obtaining gene treatment creator Piece Gene...
.Roche's constant cough plan has faltered to a stop. The drugmaker, which axed the program after the...
.Gilead Sciences as well as Merck & Co. have guided their once-weekly HIV blend treatment past on...
.Lykos Rehabs may have shed three-quarters of its personnel following the FDA's rejection of its own...
.Septerna might be yet to disclose "any type of significant clinical information," but the biotech c...